Clinical Trial

Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy

Name: Sacituzumab Tirumotecan in Pts w/ NEPC After Progression on Prior Chemotherapy — clinical trial record (NCT07639086)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: STOP-NEPC

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This is a phase 2, open-label, single-arm study of sacituzumab tirumotecan in neuroendocrine prostate cancer (NEPC) with progression after platinum-based chemotherapy.

Trial Details

NCT Number	NCT07639086
Lead Sponsor	Virginia Commonwealth University Collaborators: Merck Sharp & Dohme LLC
Conditions	Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)
Enrollment	20 participants
Start Date	2026-08-31
Primary Completion	2030-03-31 (estimated)
Study Completion	2032-03-31 (estimated)
Updated on ClinicalTrials.gov	2026-06-10